《大行報告》匯豐研究下調京東(09618.HK)目標價至324元 評級「買入」
匯豐環球研究發表報告指,京東(09618.HK)今年首季收入大致符合預期,盈利則優於預期超過七成。由於長期的疫情影響、物流中斷和較預期疲弱的消費者情緒,該行認為相關影響或會較原來預期的更拖累京東的收入,但整體影響料可因其產品組合及物流能力而得到緩衝。
該行提到,因成本管理,京東的毛利率表現估計會更有韌性,即將到來的「618」推廣亦料可推動增長復甦,指公司在「618」營運表現將決定其短期前景。
匯豐研究下調京東股份目標價,由332港元降至324港元,評級維持「買入」,並調低京東2022年至2024年收入預測2.7%至4%,至於盈利預測則分別升10.4%、1.4%及2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.